ConclusionInstead, Baulieu uses the term ‘contragestive’ to avoid, as hestates, the negative <strong>and</strong> guilt-producing associations of theword abortion. He insists that his research ‘is not aimed atgaining women abortions,’ but ‘at helping them controlgestation’ (quoted in Gardner, 1989:6). This is comparableto the reproductive technologists performing the linguisticfeat of turning a less-than-fourteen day embryo into a ‘preembryo’so as to justify embryo experimentation.Doublespeak is an attempt to make the negative appearpositive, as in the claim that RU <strong>486</strong> medicalization isdemedicalization, <strong>and</strong> strict medical supervision is privacy.Doublespeak also makes the complications appear minimal,or at least tolerable. Finally, doublespeak is a language thatcurbs thinking <strong>and</strong> acute questioning, as evidenced in thelack of any critical perspective offered by many women’sgroups.There are many reasons why individual women <strong>and</strong>women’s groups have jumped on the RU <strong>486</strong>/PGb<strong>and</strong>wagon. The packaging of the new abortifacient has beenimmensely successful. ‘The very nature of the specializedknowledge <strong>and</strong> information, the complexity of the technology,the way the ‘advances’ have been publicized in the popularmedia <strong>and</strong> such places as Science magazine, <strong>and</strong> the incrediblyslick marketing job which is being done, have had the effectof silencing criticism’ (pers. comm. to JR from Judy Luce,June 1991).Many women’s groups have taken the erosion of women’sright to abortion, as well as the fear of playing into the h<strong>and</strong>sof the right-wing, as incentive enough for promoting RU <strong>486</strong>/PG. The philosophy prevails that ‘we’—those who arecommitted to women’s rights—must be for whatever ‘they’—those who are not committed to women’s rights, i.e. the antiabortionists—areagainst. However, this defense of RU <strong>486</strong>/PG has been too much defined by a reaction to the rightwing.It has been the purpose of this report to demonstrate that113
RU <strong>486</strong>many of the basic assumptions about RU <strong>486</strong>/PG abortionneed to be fundamentally re-examined. In light of themisleading claims <strong>and</strong> the various complications, we ask ifthese drugs are an appropriate abortion technology forwomen. Environmental engineer, Pat Hynes has elsewhereraised the crucial question that ‘As a wave of green logos<strong>and</strong> lifestyle washes over industrial countries, making peopleconscious of not putting any unnecessary synthetic chemicalsubstances on <strong>and</strong> into their body, why are women beingadvised to use synthetic’ drugs (Hynes, 1990:20)? The issuehere is not that these drugs are synthetic, but that most ofthese reproductive drugs used to intervene in women’sreproductive cycle often have serious risks <strong>and</strong>complications. Thus for the last quarter of a century, feministhealth activists have been put in the position of riskmanagement <strong>and</strong> risk communication, documenting thedownside of such technologies <strong>and</strong> drugs. At the same time,reproductive technologists, while admitting that there aresome risks, minimize them so that the technologies <strong>and</strong> drugsbecome acceptable <strong>and</strong> go forward, despite the complications.They offer studies that convince women that the risks can bemanaged <strong>and</strong> that if women want effective contraception,abortions, <strong>and</strong> children, the risks have to be lived with.At a time when the rest of the planet is being warned aboutthe risks of chemical fixes, there is an enormous increase inthe number <strong>and</strong> kinds of drugs that are being prescribed forwomen, especially in the reproductive realm. From a girl’sbirth to a woman’s death, she is often prescribed fertilitydrugs, the pill, a new generation of anti-pregnancy vaccinesthat are especially being promoted in third world countries,tranquilizers, estrogen—currently, hormone—replacementtherapy, <strong>and</strong> now RU <strong>486</strong>/PG, a haphazard combination oftwo dubious drugs. Given the short period during whichRU <strong>486</strong>/PG is effective (albeit poorly), 10–40 per cent ofthe fertilized eggs/early embryos might be expelled throughspontaneous abortion <strong>and</strong> would not require any chemical114
- Page 2 and 3:
Renate Klein is Lecturer in Women
- Page 4 and 5:
RU 486Misconceptions,Myths and Mora
- Page 6 and 7:
ACKNOWLEDGEMENTSWe would like to ex
- Page 8 and 9:
CONTENTSINTRODUCTION 1CHAPTER ONETh
- Page 10 and 11:
INTRODUCTIONInitial euphoria greete
- Page 12 and 13:
IntroductionUnfortunately, objectio
- Page 14 and 15:
Introductiondo not know or do not a
- Page 16 and 17:
Introductionused widely for years a
- Page 18 and 19:
CHAPTER ONEThe History of RU 486RU
- Page 20 and 21:
The History of RU 486consultants ar
- Page 22 and 23:
The History of RU 486Events in Fran
- Page 24 and 25:
The History of RU 486service of wom
- Page 26 and 27:
The History of RU 486The result app
- Page 28 and 29:
The History of RU 486developing cou
- Page 30 and 31:
The History of RU 486University Hos
- Page 32 and 33:
The History of RU 486pharmacovigila
- Page 34 and 35:
CHAPTER TWOClaims for RU 486/PG Abo
- Page 36 and 37:
Claims for RU 486/PG Abortionsevera
- Page 38 and 39:
Claims for RU 486/PG Abortionthe Br
- Page 40 and 41:
Claims for RU 486/PG Abortionan imm
- Page 42 and 43:
Claims for RU 486/PG Abortionby the
- Page 44 and 45:
Claims for RU 486/PG Abortionby the
- Page 46 and 47:
Claims for RU 486/PG Abortionfrom A
- Page 48 and 49:
Claims for RU 486/PG Abortioncommen
- Page 50 and 51:
Claims for RU 486/PG AbortionSome s
- Page 52 and 53:
Claims for RU 486/PG Abortionbreeze
- Page 54 and 55:
Claims for RU 486/PG Abortion18 per
- Page 56 and 57:
Claims for RU 486/PG Abortion1. RU
- Page 58 and 59:
Claims for RU 486/PG AbortionRU 486
- Page 60 and 61:
Claims for RU 486/PG Abortionwider
- Page 62 and 63:
Claims for RU 486/PG Abortionmedica
- Page 64 and 65:
Claims for RU 486/PG Abortionreligi
- Page 66 and 67:
What Is RU 486 and How Does It Work
- Page 68 and 69:
What Is RU 486 and How Does It Work
- Page 70 and 71:
What Is RU 486 and How Does It Work
- Page 72 and 73: What Is RU 486 and How Does It Work
- Page 74 and 75: What Is RU 486 and How Does It Work
- Page 76 and 77: What Is RU 486 and How Does It Work
- Page 78 and 79: What Is RU 486 and How Does It Work
- Page 80 and 81: What Is RU 486 and How Does It Work
- Page 82 and 83: What Is RU 486 and How Does It Work
- Page 84 and 85: What Is RU 486 and How Does It Work
- Page 86 and 87: What Is RU 486 and How Does It Work
- Page 88 and 89: What Is RU 486 and How Does It Work
- Page 90 and 91: The Role of Prostaglandins: Known a
- Page 92 and 93: The Role of Prostaglandins: Known a
- Page 94 and 95: The Role of Prostaglandins: Known a
- Page 96 and 97: The Role of Prostaglandins: Known a
- Page 98 and 99: The Role of Prostaglandins: Known a
- Page 100 and 101: The Role of Prostaglandins: Known a
- Page 102 and 103: The Role of Prostaglandins: Known a
- Page 104 and 105: The Role of Prostaglandins: Known a
- Page 106 and 107: The Role of Prostaglandins: Known a
- Page 108 and 109: The Role of Prostaglandins: Known a
- Page 110 and 111: The Role of Prostaglandins: Known a
- Page 112 and 113: The Role of Prostaglandins: Known a
- Page 114 and 115: The Role of Prostaglandins: Known a
- Page 116 and 117: The Role of Prostaglandins: Known a
- Page 118 and 119: The Role of Prostaglandins: Known a
- Page 120 and 121: The Role of Prostaglandins: Known a
- Page 124 and 125: Conclusionintervention. Thus, RU 48
- Page 126 and 127: Conclusionbetween population contro
- Page 128 and 129: ConclusionThis article, appearing i
- Page 130 and 131: Conclusion‘a whole net of relatio
- Page 132 and 133: ENDNOTESChapter One1The paten t lic
- Page 134 and 135: Endnotes12The Journal Officiel publ
- Page 136 and 137: Endnotesin Gynecology and Obstetric
- Page 138 and 139: Endnotesof menses. On the third day
- Page 140 and 141: EndnotesAnother such example is the
- Page 142 and 143: Bibliographyand Segal, Sheldon (Eds
- Page 144 and 145: Bibliographyprostaglandin F 2•. A
- Page 146 and 147: BibliographyDelaney, Anne. (1991, 2
- Page 148 and 149: Bibliographyresponses to the steroi
- Page 150 and 151: Bibliographyabnormalities resulting
- Page 152 and 153: Bibliographyprogesterone receptor b
- Page 154 and 155: BibliographyOdlind, Viveca and Birg
- Page 156 and 157: BibliographyBinding of the anti-pro
- Page 158 and 159: BibliographyUlmann, André, Teutsch
- Page 160: Bibliographytermination by vacuum a